title: Psychopharmacological treatment in borderline personality disorder.
abstract: Borderline personality disorder is a disorder with important social and clinical repercussions, which has been treated mainly by psychotherapy. In recent years, the syndromic analysis of this disorder has allowed us to identify different symptoms capable of being improved with psychopharmacology treatment. Thus, its complex symptomatology could be included in four clinical dimensions: impulsive-aggressive, affective instability, cognitive- perceptive and anxiety-inhibition. Antidepressants, mood stabilizers, antipsychotics, anxiolytics, or more recently omega-3 fatty acids have shown efficacy in the treatment of symptomatic dimensions of this disease. We have reviewed scientific articles (reviews, clinical trials or clinical guidelines) published over the last ten years and have proposed therapeutic algorithms for psychopharmacology management in these patients.
authors.affiliation: Hospital Clínico San Carlos, Madrid, Spain. mdiazm.hcsc@salud.madrid.org
authors.forename: M
authors.initials: M
authors.lastname: Díaz-Marsá
authors.forename: S
authors.initials: S
authors.lastname: González Bardanca
authors.forename: K
authors.initials: K
authors.lastname: Tajima
authors.forename: J
authors.initials: J
authors.lastname: García-Albea
authors.forename: M
authors.initials: M
authors.lastname: Navas
authors.forename: J L
authors.initials: JL
authors.lastname: Carrasco
mesh_terms: D000374:Aggression / Q000523:psychology; D000679:Amygdala / Q000378:metabolism / Q000503:physiopathology; D000928:Antidepressive Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D001883:Borderline Personality Disorder / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy*; D003346:Corticotropin-Releasing Hormone / Q000378:metabolism; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000175:diagnosis / Q000453:epidemiology; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use; D005473:Fluoxetine / Q000627:therapeutic use; D006624:Hippocampus / Q000378:metabolism / Q000503:physiopathology; D006801:Humans; D016651:Lithium Carbonate / Q000627:therapeutic use; D000077152:Olanzapine; D012688:Septum Pellucidum / Q000378:metabolism / Q000503:physiopathology; D012701:Serotonin / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D020280:Sertraline / Q000627:therapeutic use; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
chemical_list: D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D001569:Benzodiazepines; D003346:Corticotropin-Releasing Hormone; D015525:Fatty Acids, Omega-3; D005473:Fluoxetine; D016651:Lithium Carbonate; D000077152:Olanzapine; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline; D005680:gamma-Aminobutyric Acid